Pharma BD Deal Intelligence
Allergan Inc. / MAP Pharmaceuticals Inc.
2013 · Acquisition/Merger · $958M · Complete
Announcement Sentiment
50
Neutral / mixed
Allergan to acquire MAP at $25/share (~$958M, 60% premium) to expand neurology/migraine franchise via Levadex orally inhaled DHE; cash tender + back-end merger.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 5yr post-close.
Key facts
- Announced Jan 22, 2013
- Closed Mar 01, 2013
- Deal value $958M
- Deal type Acquisition/Merger
- Therapeutic area Acute migraine in adults
- Indications Acute migraine in adults
- Key assets Levadex (dihydroergotamine orally inhaled)
- Mechanism Inhaled DHE (dihydroergotamine) — 5-HT1B/1D agonist
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals